Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Jan 3 2020

Full Issue

If FDA Can't Even Decide If CBD Supplements Are Legal, Do Disgruntled Consumers Have A Standing In Court?

Consumers are filing lawsuits claiming that makers of CBD supplements engaged in “false, fraudulent, unfair, deceptive, and misleading” marketing of their products. But the FDA has struggled to set clear rules of the road over regulations for the industry, muddying the waters for the consumers. In other public health news: taboo topics about women's health, superfund sites, recalls, and more.

Stat: A Spate Of New Class-Action Lawsuits Threaten The CBD Industry 

Since the Food and Drug Administration can’t figure out whether supplements that contain cannabidiol, the marijuana-adjacent oil known as CBD, are legal, can a customer who thought they were buying a legal product demand their money back? A group of remorseful CBD users is suing to test that theory, and it’s going after the companies that put CBD on the map. (Florko, 1/3)

Kaiser Health News: ‘Grade A’ All-American Pot: The Next Big Export?

In a large warehouse, LivWell Enlightened Health feeds its cloned cannabis plants a custom blend of nutrients, sprays them with filtered water and pumps extra carbon dioxide into the air. LivWell releases three types of insects to clear the plants of unwanted pests without the use of toxic pesticides. Every part of the growing process is meticulously documented and evaluated to constantly refine the process. (Hawryluk, 1/3)

NPR: These Women's Health Taboos Are Overdue To Be Busted

As the decade changes and we consider the state of women's health in America, who better to turn to than the authors of five taboo-busting books from 2019 that took on issues that generations of women haven't been talking about, but need to. We asked these outspoken doctors and health advocates to give us their Top 7 messages to women for 2020. Here's what they said. (Vaughn, 1/2)

The Associated Press: Backlog Of Toxic Superfund Clean-Ups Grows Under Trump

The Trump administration has built up the biggest backlog of unfunded toxic Superfund clean-up projects in at least 15 years, nearly triple the number that were stalled for lack of money in the Obama era, according to 2019 figures quietly released by the Environmental Protection Agency over the winter holidays. The accumulation of Superfund projects that are ready to go except for money comes as the Trump administration routinely proposes funding cuts for Superfund and for the EPA in general. (Knickmeyer, Brown and White, 1/3)

Sacramento Bee: Mislabeling Causes Recall Of Clinical Depression Medication

One lot of clinical depression treatment Mirtazapine has been recalled because the tablets in the bottle might be twice as strong as the bottle’s label indicates. Aurobindo’s FDA-posted recall notice says the labels on lot No. 03119002A3, expiration 03/2022, say the 500-count bottles should have 7.5 mg tablets of the medicine also sold under the brand name Remeron. Problem is, the bottles might have 15 mg tablets. (Neal, 1/2)

The Wall Street Journal: Transit Systems Take On Role As Homeless Advocates

Jeffrey Knueppel’s skills include running trains, buses and subways, and helping people who are homeless find jobs and housing. The retired general manager of the Philadelphia region’s transit authority, like a growing number of transit officials around the country, increasingly assumed a social-welfare role in recent years as his agency struggled to cope with rising homelessness. The Southeastern Pennsylvania Transportation Authority spent more than $1 million partnering with the city of Philadelphia to build an 11,000-square-foot homeless drop-in center at a busy subway station. (Berger, 1/2)

Axios: The U.S. Has 1.1 Million Fewer Kids Than At The Start Of The Decade

There are 1.1 million fewer children living in the U.S. today than there were at the start of the decade, according to an analysis of new Census data by the Brookings Institution's William Frey. The big picture: The adult population grew by 8.8% in the 2010s. in the three previous decades, the child population increased. The past decade marks a pivotal moment as the U.S. ages and, as a result, family life is transformed — especially because Americans are waiting longer to have children and having fewer of them. (Kight, 1/2)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF